Email us for help
Loading...
Premium support
Log Out
Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.
PRE-RECORDED... December 2010, hosted by BJ Viau
Robert Pacifici was the Site Director and Chief Scientific Officer at the Research Triangle Park Laboratories of Eli Lilly and Company. There he oversaw the company's global screening and quantitative-biology efforts. Prior to joining Lilly, Robert was Vice President of Discovery Technologies at Xencor, a privately held biotechnology company that applied rational design principles to the development of protein therapeutics. At Amgen for nearly ten years, Pacifici’s responsibilities increased. He led their automation, high throughput screening, and information technologies groups. In addition, he was instrumental in forging Amgen's relationships with Caliper Technologies and The Automation Partnership as well as the acquisition of Kinetix Pharmaceuticals. Robert received a BS in Biochemistry from the University of Massachusetts, Amherst, and a PhD in Biochemistry from the University of Southern California. He holds an adjunct appointment at the University of Southern California's Department of Molecular Pharmacology and Toxicology. He is also Chair of the Spinal Muscular Atrophy Project's Scientific Steering Committee, which is part of the National Institute on Neurological Disorders and Stroke (NINDS). He currently sits on several additional external boards and advisory committees, including the Cooperative International Neuromuscular Research Group, SMA Foundation, and TREAT ALS Steering Committee. He joined CHDI in 2004.